Research Notes on New York Times Report on Zetia
Zetia, the most common brand name for Ezetimibe, is a new kind of cholesterol-lowering drug. It acts by diminishing the absorption of dietary cholesterol through the intestines.
Top Resources on New York Times Report on Zetia
- New York Times: Data About Zetia Risks Was Not Fully Revealed
- HealthDay (via MSN Health and Fitness): Cholesterol Drug Zetia Doesn't Cut Heart Attack Risk
- New York Times (via Medical Marketing and Media): Zetia marketers never fully revealed liver risks
- New York Times: Study Reveals Doubt on Drug for Cholesterol
- New York Times: Trial of Cholesterol Drug Gets House Scrutiny
- New York Times: After a Trial, Silence
User Recommended Links for New York Times Report on Zetia
Are we missing any great links? Please Login or Register to be the first to add to this list of recommended links to help others and improve this WisdomCard.
About this WisdomCard
- Contributor: Chris Miller
- Reviewer: Tara
- Supervised by: The OrganizedWisdom Physician Review Team
- Last update: Sep. 10, 2008
Each WisdomCard is handcrafted by our team of physician-guided health advocates. Our goal is to make it easy for you to find the most useful health resources for any health topic. In addition to filtering out spam and bad links, WisdomCards highlight tips and warnings, such as:
- Guide Favorite
- Guide Warning
- Scroll down to reach relevant content
- Video
- In Memoriam
Help improve this WisdomCard by suggesting great links.
